Century Tx (IPSC) - Market Cap to Net Income Ratio

Market fluctuations in Century Therapeutics (IPSC) shares reflect the asset's dynamics, with a metric of -3.00. Century Therapeutics focuses on developing affordable, off-the-shelf cell products to eliminate the complexities of personalized synthesis. The business leverages innovative CRISPR tooling, creating a powerful moat against competitors. Meanwhile, the current expansion of laboratory capacities is leading to a proportional increase in sterile zone expenditures.

IPSC centurytx.com: Price to Earnings Ratio in the range 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for Century Tx (IPSC)

- market price and analyst price targets:

Market Price Century Therapeutics Inc|IPSC - Analyst Consensus Forecast

- market capitalization indicators:

Market Capitalization Century Therapeutics, Inc.|IPSC - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Net Asset Value per Share Century Therapeutics|IPSC - Company Net Assets|Market Value to Book Value centurytx.com|IPSC - Company Total Assets

- debt obligations and liquidity statistics:

Total Debt to Equity Ratio Century Therapeutics|IPSC - Long-Term Debt to Capital|Current Liabilities to Capital Century Therapeutics Inc|IPSC - Company Debts|Debt to Book Capitalization Ratio Century Therapeutics, Inc.|IPSC - Company Long-Term Debt|Company Short-Term Debt Century Therapeutics|Intermediate Coverage Ratio centurytx.com

- business earnings and investment ratios data:

IPSC - Net Profit|Projected Net Profit Century Therapeutics|IPSC - P/E Multiple|Projected Price to Earnings Ratio Century Therapeutics Inc|IPSC - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Century Therapeutics, Inc.|IPSC - Operating profit EBITDA|Net earnings per one share for the last twelve months Century Therapeutics|IPSC - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months centurytx.com|IPSC - Net earnings per share growth this year|Projected earnings per share increase next year Century Therapeutics

- issuer revenue and sales details:

IPSC - Revenue and Sales Volume|Company Future Revenue Century Therapeutics Inc|IPSC - P/S Multiple|Market Cap to Future Revenue Ratio Century Therapeutics, Inc.

Comprehensive company analysis:centurytx.com

Signature product of Century Therapeutics, Inc.

This multiple is calculated as the ratio of market capitalization to net income, allowing for an assessment of the cost of one dollar of the issuer's earnings. Since Century Therapeutics (IPSC) is in the clinical trial stage and has not yet established a commercial base, the company's fundamental P/E multiple reflects speculative market expectations regarding the future monetization of its allogeneic cell platform.

Analysis of competing companies